Trial intelligence / Profile preview

MATVAC-1

2024-514399-42-00Phase 2Authorised

Sponsor: CHRU Nancy
Start: Nov 2025
Modality: Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Classical Binding Small Molecules → Small Molecules
Countries: 1

Overview

Phase 2, randomised trial in glioblastoma (GBM) comparing UCPVax + standard adjuvant temozolomide with UCPVax + pembrolizumab + standard adjuvant temozolomide (2 arms). Primary endpoint: Rate of patients alive at 18 months post randomization (per experimental arm). Planned start Nov 2025; status: authorised.

Drugs

pembrolizumabUCPVaxtemozolomide

Conditions

glioblastoma (GBM)

Beyond the preview

Go deeper on 2024-514399-42-00.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2024-514399-42-00.